698 related articles for article (PubMed ID: 34864500)
1. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Sisi M; Fusaroli M; De Giglio A; Facchinetti F; Ardizzoni A; Raschi E; Gelsomino F
Target Oncol; 2022 Jan; 17(1):43-51. PubMed ID: 35025076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
8. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Wang F; Xu G; Wu X
Expert Opin Drug Saf; 2023; 22(11):1127-1132. PubMed ID: 37428255
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
10. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
11. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
[TBL] [Abstract][Full Text] [Related]
13. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
14. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
[TBL] [Abstract][Full Text] [Related]
15. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
Nicholls C; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
18. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
19. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
Tang S; Wu Z; Xu L; Wen Q; Zhang X
Front Pharmacol; 2022; 13():970066. PubMed ID: 36263117
[No Abstract] [Full Text] [Related]
20. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
Zhao M; Liu S; Xie R; Zhang J; Li J
Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
